AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04396652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block and IPACK block group
Description: Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
Study NCT01408706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller Air tip
Description: Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
Study NCT01408706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiadyne Immobilizer
Description: Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
Study NCT02447419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg will be administered orally daily
Study NCT04092738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk@WorkApp-Diab
Description: The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
Study NCT03798743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined With Docetaxel
Description: Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
Study NCT03772808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycocomfort
Description: Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
Study NCT04151069 — intervention group
Intervention type: OTHER
Intervention: Procedure A
Description: Up-dosing nut drink at home
Study NCT04151069 — intervention group
Intervention type: OTHER
Intervention: Procedure B
Description: Up-dosing nut drink at the hospital
Study NCT04151069 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: Strict avoidance of tree nut consumption
Study NCT03022006 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: elbasvir, grazoprevir
Study NCT01766362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRPC using Pascal laser
Study NCT01766362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PRPC using Pascal laser
Study NCT02979782 — intervention group
Intervention type: PROCEDURE
Intervention: Endo-CABG
Description: minimal invasive cardiac intervention
Study NCT02979782 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: stenting procedure
Study NCT04157010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study NCT04157010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT03444844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 P16-093 PET/CT scan
Description: IV injection followed by PET/CT scanning
Study NCT02869789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with Ipilimumab
Description: Specified dose on specified days
Study NCT00230048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computer-delivered intervention
Description: Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
Study NCT03628651 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: HCC subjects will have one blood sample collected.
Study NCT03628651 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
Study NCT00575354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
Study NCT00575354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: 3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
Study NCT02909010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS™ Brain Monitoring System
Description: The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
Study NCT02909010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RASS
Description: control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
Study NCT01460732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blood Pressure Monitoring
Description: Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
Study NCT02911649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - Garmin Vivosmart
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Study NCT02504983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
Study NCT02504983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
Study NCT02504983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
Study NCT02911649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Educational Group
Description: A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
Study NCT02911649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - FitBit Alta
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Study NCT02911649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Technology - Polar Loop 2
Description: Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
Study NCT00842634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZFN modified T cells
Description: A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
Study NCT00842634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruption
Description: Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
Study NCT04458519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiorinse
Description: Nasal irrigations with probiotic twice-daily for a period of fourteen days
Study NCT04458519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: Nasal irrigations with saline-only twice-daily for a period of fourteen days
Study NCT04623866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huaiqinhuang
Description: Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
Study NCT04623866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Valsartan granules 80mg/1.73m2 based qd 24 weeks
Study NCT03851263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
Study NCT04283786 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
Study NCT01564004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis or neuro-linguistic programming
Description: 20 minutes tape recording intervention
Study NCT01564004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical hypnosis or neuro-linguistic programming
Description: 20 minutes tape recording intervention
Study NCT04823780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrient solution
Description: For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
Study NCT04620577 — intervention group
Intervention type: OTHER
Intervention: antibiotic
Description: normal saline
Study NCT01012427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous cryoablation
Description: All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase > 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
Study NCT01500798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg bardoxolone methyl
Description: 20 mg, oral, once daily
Study NCT01500798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily
Study NCT01644721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Early measles vaccine
Description: Standard Edmonston-Zagreb measles vaccine
Study NCT03511677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Customized insole
Study NCT03511677 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Insole
Description: Placebo flat insole
Study NCT03352076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Danazol
Description: Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
Study NCT03352076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Danatrol
Description: Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
Study NCT02991365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal insulin
Study NCT02991365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo spray
Study NCT02127658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene education
Description: Participants will receive specific hygiene instructions according to existing recommendations.
Study NCT02127658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
Study NCT02127658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
Study NCT03159598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Glu
Description: Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
Study NCT03159598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Glu
Description: Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
Study NCT03159598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drain
Description: Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
Study NCT03159598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
Study NCT03159598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
Study NCT02541617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Programming by community Neurologist
Description: Deep Brain stimulator with be programmed by a community Neurologist
Study NCT00371189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline.
Study NCT00371189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Description: Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.
Study NCT04557267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose
Description: Dosage 1
Study NCT04557267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle-dose
Description: Dosage 2
Study NCT04557267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-dose
Description: Dosage 3
Study NCT04557267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04651140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
Study NCT04161053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 550 mg twice daily for 6 months
Study NCT04161053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500 mg twice daily for 6 months
Study NCT02344264 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
Study NCT02344264 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
Study NCT02541617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Deep Brain Stimulator will be programmed with at the implanting movement disorders center
Study NCT03054051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tumaini Mobile Phone Game
Description: Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
Study NCT03937518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Strontium Ranelate
Description: Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (
Study NCT03937518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis
Study NCT01207947 — intervention group
Intervention type: DRUG
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Patients under daily life treatment receiving Levitra according to local drug information.
Study NCT04216147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE
Description: Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
Study NCT04216147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for CTS
Description: Median nerve release
Study NCT02590666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar Polypectomy
Description: Polyps resection with bipolar electrode
Study NCT02590666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Polypectomy
Description: Polyps resection with microscissors or graspers
Study NCT02590666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar electrode
Description: Bipolar electrode used to performs polypectomy
Study NCT02590666 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microscissors or graspers
Description: Mechanical instruments used to performs polypectomy
Study NCT02718664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (breakfast)
Description: Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
Study NCT03132545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SenseWear Armband (SWA) monitoring
Description: Participants wore the SWA on their right arm
Study NCT03132545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: total body dual-energy X-ray absorptiometry
Description: DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
Study NCT02060500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiaplication
Study NCT03540264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil Majesty TM
Description: Tooth wear - composite resin
Study NCT03540264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vita-Enamic®
Description: Tooth wear - polymer-infiltrated-ceramic-network